It also exhibited antitumor effects in neuroendocrine lung cancers and lymphoma patient-derived xenografts.492 MRT-2359 is undergoing a Phase I/II clinical trial to evaluate its efficacy in treating MYC-driven cancers such as NSCLC, SCLC, high-grade neuroendocrine cancers, and diffuse large B-cell lymphoma (NCT05546268). Here, MYC is linked to non-small cell lung carcinoma.